



November 8, 2018

Edwards Lifesciences, LLC
Ye Kim
Senior Specialist, Regulatory Affairs
One Edwards Way
Irvine, California 92614

Re: K181684

Trade/Device Name: VAMP Plus Venous/Arterial Blood Management Protection System
Regulation Number: 21 CFR 870.1210
Regulation Name: Continuous flush catheter
Regulatory Class: Class II
Product Code: KRA
Dated: October 5, 2018
Received: October 9, 2018

Dear Ye Kim:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Michael John -S

2018.11.08 11:03:48 -05'00'

for Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K181684

Device Name

VAMP Plus Venous/Arterial Blood Management Protection System

Indications for Use (Describe)

To be used only for blood withdrawal.

The blood sampling system is indicated for use on patients requiring periodic withdrawal of blood samples from arterial and central line catheters, including peripherally inserted central catheters and central venous catheters, which are attached to pressure monitoring lines.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

SECTION 5 – 510(k) SUMMARY

510(k) Submitter	Edwards Lifesciences, LLC	
Contact Person	Primary Contact Ye Seul Kim Senior Specialist, Regulatory Affairs Edwards Lifesciences One Edwards Way Irvine, CA 92614 Tel: (949) 250 – 2445 Fax: (949) 809 – 5425 Email: yeseul_kim@edwards.com	Secondary Contact Renate MacLaren Senior Manager, Regulatory Affairs Edwards Lifesciences One Edwards Way Irvine, CA 92614 Tel: (949) 250 – 5783 Fax: (949) 809 – 2941 Email: renae_maclaren@edwards.com
Date Prepared	June 25, 2018	
Trade Name	VAMP Plus Venous/Arterial Blood Management Protection System	
Common Name	Closed Blood Sampling System	
Classification Name	Catheter, Continuous Flush (21 CFR 870.1210)	
Regulation Class/Product Code	Class II KRA	
Primary Predicate Device	K161962: VAMP Plus Venous/Arterial Blood Management Protection System (Cleared on November 28, 2016)	
Secondary Predicate Device	K173586: VAMP Venous/Arterial Blood Management Protection System (VAMP Adult) (Cleared on April 5, 2018)	
Device Description	The Edwards <u>V</u>enous/<u>A</u>rterial <u>B</u>lood <u>M</u>anagement <u>P</u>rotection (VAMP) Systems are sterile, single use devices that provide a safe and convenient method for the withdrawal of blood samples when attached to pressure monitoring lines. The VAMP Plus device is a needleless closed blood sampling system designed to reduce infection, needle sticks, and blood waste associated with blood sampling. One family of VAMP product line, the VAMP Plus blood sampling system, is the subject of this submission. The VAMP Plus Venous/Arterial Blood Management Protection System (VAMP Plus) is designed for use with disposable and reusable pressure transducers and for connection to central line catheters (inclusive of peripherally inserted central catheters and central venous catheters) and arterial catheters where the system can be flushed clear after sampling. The VAMP Plus blood sampling system is used for the drawing and retention of heparinized/diluted blood (or clearing volume) from the catheter or cannula within the line, allowing undiluted blood samples to be drawn from an in-line sampling site. At the completion of the sample draw, the mixed heparin and blood solution (clearing volume) is reinfused into the patient to reduce fluid loss to the patient.	

Indications for Use/Intended Use	To be used only for blood withdrawal. The blood sampling system is indicated for use on patients requiring periodic withdrawal of blood samples from arterial and central line catheters, including peripherally inserted central catheters and central venous catheters, which are attached to pressure monitoring lines.
Comparative Analysis	The subject device is identical to the predicate devices in terms of intended use/ indications for use, and technology. The proposed changes to the device include a change of sterilization method (100% Ethylene Oxide to E-beam radiation); change in the PVC plasticizer from DEHP to the non-phthalate plasticizer, 1, 2-cyclohexane dicarboxylic acid diisononyl ester (DINCH®) for the tubing; update of product labeling to reflect changes in sterilization method (from EO to E-beam radiation) and removal of phthalate symbol on all levels of packaging; introduction of an additional sampling site, Luer Activated Sampling Site (cleared in K173586) to replace the Z-site in some of the VAMP Plus models. Testing was conducted to ensure that the change in sterilization method and change in materials did not alter the performance of the VAMP Plus blood sampling system. The subject VAMP Plus blood sampling system has been shown to be substantially equivalent to the predicate devices for its intended use in hospitals and other appropriate clinical environments.
Functional/ Safety Testing	The VAMP Plus blood sampling system has successfully passed functional and performance testing, including packaging, shelf life, sterilization, biocompatibility, chemical characterization and bench testing that includes overpressure leak testing, negative leak testing, pressure tubing pull testing and frequency response testing.
Conclusion	The VAMP Plus blood sampling system is substantially equivalent to the predicate devices, the VAMP Plus Venous/Arterial Blood Management Protection Systems (K161962) and the VAMP Venous/Arterial Blood Management Protection System (VAMP Adult) (K173586).